# Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

> **NCT00957047** · PHASE3 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 395 (actual)

## Conditions studied

- Partial Epilepsy

## Interventions

- **DRUG:** eslicarbazepine acetate
- **DRUG:** placebo
- **DRUG:** ESL - Part II

## Key facts

- **NCT ID:** NCT00957047
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2006-08
- **Final completion:** 2008-01
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00957047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00957047, "Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00957047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*